Tempus AI (TEM)
Links clinical testing, multimodal data, and AI applications across precision medicine.
Something off on this page? Send us feedback.
Sells oncology and hereditary diagnostics alongside data licensing, clinical-trial services, care-pathway software, and algorithmic applications. A shared multimodal data platform connects the testing and data businesses within one reportable segment, with operations based in Chicago and an extension into Japan through a joint venture.
Combines clinical diagnostics with a multimodal data platform for physicians and life-sciences customers. Diagnostics spans oncology and hereditary testing, while Data and applications includes Insights, Next, Trials, and Algos.
Laboratory testing generates molecular and clinical data that can be structured and de-identified for licensing, research, trial matching, care-gap identification, and algorithmic tools. This feedback loop connects the testing business with the software and data products.
Based in Chicago, the business operates as one reportable segment and extends its model into Japan through the SB Tempus joint venture. Execution depends on payer coverage and reimbursement, pharmaceutical and biotechnology research budgets, compliance with health-data and AI rules, and integration of acquired laboratories, datasets, software, and teams.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 21, 2026 | Goldman Sachs | Initiate | Rating: —Target: — | Target: $75 |
| Sep 11, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $56 | Target: $66 |
| Sep 9, 2026 | UBS | Initiate | Rating: —Target: — | Target: $70 |
| Sep 8, 2026 | Redburn Partners | Target | Target: — | Target: $67 |
| Sep 2, 2026 | Raymond James | Target | Target: — | Target: $80 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $816.0M · Total debt $1.44B · Total assets $2.37B · Shareholders' equity $444.9M
- Revenue
- $382.5M
- Operating income
- −$75.9M
- Net income
- $5.6M
No dividends on record.
| Institutions | 61.78% | 111.48M shares | |
|---|---|---|---|
| 542 holders · as of Jun 30, 2026 | |||
| Insiders | 32.53% | 58.69M shares | |
| 13 holders · as of Sep 18, 2026 | |||
| Strategic holders | 17.28% | 31.17M shares | |
| 1 holder · as of Dec 12, 2024 | |||
| Adds to | 111.59% | ||
180.43M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 111.59%; nothing is left for Other.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Eric P. Lefkofsky1,2,3Insiderdirector, 10 percent owner, officer: CEO and Chairman | 23.70% | 24.40M A | filed Feb 10, 2026 |
Red Sky Ventures LLC4Strategic10 percent owner | 17.28% | 31.17M A | filed Dec 12, 2024 |
Bradley A. KeywellInsider10 percent owner | 8.43% | 15.22M A | filed Jan 22, 2025 |
Ark Investment Management LLCInstitution | 5.55% | 10.02M A | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 4.60% | 8.29M A | as of Jun 30, 2026 |
- Eric P. Lefkofsky reports a block also reported by Geode Capital Management, LLC; it is counted once, under Geode Capital Management, LLC.
- Eric P. Lefkofsky reports a block also reported by JPMorgan Chase & Co; it is counted once, under JPMorgan Chase & Co.
- The filed share classes (A, COMMON) could not be matched to the company's, so no percentage.
- Reported at 4.70% on Nov 13, 2025, under the 5% line, so no further filing is required.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 16, 2026 | Ryan Fukushima | officer: CEO, Data | −700 | $70.00 |
| Sep 17, 2026 | Andrew Polovin | officer: EVP, Chief Legal Officer | −2,951 | $75.00 |
| Sep 17, 2026 | Ryan M. Bartolucci | officer: Chief Accounting Officer | −7,062 | $75.00 |
| Sep 17, 2026 | Eric P. Lefkofsky | director, 10 percent owner, officer: CEO and Chairman | −200,000 | $80.57 |
| Sep 1, 2026 | David R. Epstein | director | −250 | $65.55 |
- Caris Life Sciences
Closest public peer in tumor profiling, liquid biopsy, and oncology data
- Guardant Health
Direct rival in oncology testing, MRD, and clinico-genomic data
- Natera
Major MRD rival with adjacent tumor profiling and hereditary testing
- NeoGenomics
Oncology lab network spanning diagnostics, MRD, trials, and data
- IQVIA
Scaled rival in life-sciences data, real-world evidence, and trials
- GeneDx
Direct hereditary-testing rival built on clinical exome and genome sequencing
- Myriad Genetics
Hereditary cancer and neuropsychiatric pharmacogenomics competitor
- Labcorp
Large lab rival in oncology, hereditary genetics, and MRD testing
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Tempus AI | $77.64 | −0.50% | $13.67B | — | — | 9.5 | +21.6% |
| Caris Life Sciences | $32.08 | +4.67% | $8.66B | 85.6 | 127.4 | 8.8 | +45.4% |
| Guardant Health | $177.63 | +2.16% | $23.33B | — | — | 19.7 | +44.3% |
| Natera | $387.32 | +4.50% | $53.08B | — | — | 19.6 | +37.7% |
| NeoGenomics | $19.13 | −1.44% | $498.7M | — | 68.8 | 0.7 | +11.2% |
| IQVIA | $271.78 | +0.70% | $44.42B | 33.5 | 20.0 | 2.6 | +8.7% |
| GeneDx | $89.54 | −8.48% | $2.92B | — | 137.1 | 6.4 | +11.4% |
| Myriad Genetics | $3.93 | −2.00% | $378.7M | — | — | 0.5 | −10.5% |
| Labcorp | $310.04 | −3.41% | $26.32B | 26.6 | 16.4 | 1.8 | +5.8% |
| Median | 33.5 | 68.8 | 4.5 | +11.3% |